Sort
40,608 grants matching “prostate cancer”
Mechanisms of Radioresistance and Cell Cycle Progression
$347,814Howard B Lieberman · Columbia University Health Sciences · R01 · FY2016 · CA
Mechanisms of Radioresistance and Cell Cycle Progression
$347,814Howard B Lieberman · Columbia University Health Sciences · R01 · FY2012 · CA
Mechanisms of Radioresistance and Cell Cycle Progression
$347,814Howard B Lieberman · Columbia University Health Sciences · R01 · FY2015 · CA
MECHANISM OF STEROID SPECIFIC GENE ACTIVATION
$347,810University Of Michigan At Ann Arbor · R01 · FY2003 · DK
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer
$347,758Kaustubh Datta · University Of Nebraska Medical Center · R01 · FY2021 · CA
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer
$347,758Kaustubh Datta · University Of Nebraska Medical Center · R01 · FY2020 · CA
Automatic Pelvic Organ Delineation in Prostate Cancer Treatment
$347,700Dinggang Shen · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA
Automatic Pelvic Organ Delineation in Prostate Cancer Treatment
$347,700Jun Lian · Univ Of North Carolina Chapel Hill · R01 · FY2018 · CA
Neuroendocrine differentiation post anti-androgenic therapy: Role of Tribbles 2
$347,700Jagadananda Ghosh · Henry Ford Health System · R01 · FY2025 · CA
The Impact of Aging on Prostate Cancer with Age-Related Disruption of Th17/Treg Axis
$347,700Qiuyang Zhang · Tulane University Of Louisiana · R01 · FY2025 · CA
The Impact of Aging on Prostate Cancer with Age-Related Disruption of Th17/Treg Axis
$347,700Qiuyang Zhang · Tulane University Of Louisiana · R01 · FY2021 · CA
Neuroendocrine differentiation post anti-androgenic therapy: Role of Tribbles 2
$347,700Jagadananda Ghosh · Henry Ford Health System · R01 · FY2023 · CA
Interference with Androgen Receptor and Its Ligands
$347,662James L Mohler · Univ Of North Carolina Chapel Hill · P01 · FY2011 · CA
Prevention and Treatment of Impotence
$347,659Tom F Lue · University Of California, San Francisco · R37 · FY2006 · DK
Stealth Brusatol and Docetaxel-loaded Nanoparticles for Targeted Prostate Cancer Therapy
$347,625Simeon Kolawole Adesina · Howard University · SC1 · FY2021 · GM
THE ROLE OF SF2 IN PROSTATE CANCER PROGRESSION
$347,625Thomas Jefferson University · · FY2010 · Department of the Army
CDK inhibitors in tumor progression
$347,600Andrew Koff · Sloan-Kettering Inst Can Research · R01 · FY2009 · CA
PHASE II TRIAL OF SOY PRIOR TO RADICAL PROSTATECTOMY
$347,594New York University School Of Medicine · R01 · FY2004 · CA
Mechanisms of Carcinoma Differentiation and Invasion
$347,563Arthur M Mercurio · Univ Of Massachusetts Med Sch Worcester · R01 · FY2015 · CA
Mechanisms of Carcinoma Differentiation and Invasion
$347,563Arthur M Mercurio · Univ Of Massachusetts Med Sch Worcester · R01 · FY2016 · CA
Molecular Determinants of Androgen Receptor Pharmacology
$347,562Donald P McDonnell · Duke University · R01 · FY2011 · CA
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer
$347,533Dolores Di Vizio · Cedars-Sinai Medical Center · R01 · FY2020 · CA
Race-related alternative splicing: novel targets in prostate cancer
$347,517Steven R Patierno · Duke University · R01 · FY2021 · CA
Race-related alternative splicing: novel targets in prostate cancer
$347,517Steven R Patierno · Duke University · R01 · FY2020 · CA
Clinical Trials with Immunotoxins
$347,508Ira Pastan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA